FdaApplication
NDA 216227
Identifiers
- fda_app_no: NDA216227
Properties
| Property | Value |
|---|---|
| applicant_name | HARROW EYE LLC |
| application_type | NDA |
| approval_date | 2022-09-27 |
Revenue by product
IHEEZO
| Period | Revenue |
|---|---|
| Q2 2026 | $15.6M |
| Q1 2026 | $1.9M |
| Q4 2025 | $35.9M |
| Q3 2025 | $21.9M |
| Q2 2025 | $36.7M |
| Q1 2025 | $5.2M |
| Q4 2024 | $22.8M |
| Q3 2024 | $12.9M |
| Q2 2024 | $11.3M |
| Q1 2024 | $2.3M |
| Q4 2023 | $10.5M |
| Q3 2023 | $5.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| IHEEZO | CHLOROPROCAINE HYDROCHLORIDE | 3% | GEL;OPHTHALMIC |
1 product